Other Clinical Trial - An Extension Protocol for Patients Who Previously

Status Terminated

Clinical Trial Summary

This is an open-label extension study to continue to evaluate the safety, tolerability and efficacy of the Repetitive Transcranial Magnetic Stimulation (rTMS) in subjects with schizophrenia or schizoaffective disorder who previously completed the treatment study of the protocol #8116 (NCT05319080). Protocol #8116 investigates the clinical efficacy of open-label individualized MRI-guided TMS applied to the left temporoparietal junction (TPJ) in schizophrenia patients. Participating patients who have completed the 4-week project #8116 can be screened for eligibility for this extension study in which they will continue treatment/assessment. They will be divided into three groups (non-responders, partial responders, or full responders) based on a reduction in the Auditory Hallucination Rating Scale (AHRS) scores from the study #8116.

Clinical Trial Description

The optimal neuroanatomical treatment targets remain unclear, though current neuroscience evidence suggests several brain areas such as the left temporo-parietal junction area (TPJ) or the right posterior superior temporal sulcus (rSTS) may be involved in the generation and development of AVH. During this extension study, non-responders to protocol #8116 will be administered 10 days (10 sessions) of MRI-guided 1 Hz rTMS delivered to the rSTS instead of the original target in TPJ. Partial responders will receive 10 additional low-frequency rTMS over the original left TPJ target. Like the protocol #8116, the investigators will use the MRI-guided targeting approach during rTMS treatment sessions to achieve greater precision as it can account for individual differences in anatomy. Complete responders will instead be followed for sustainability of response. Their clinical ratings will be repeated at one week, two week, four week and eight week follow-ups. Non-responders are defined as patients showing a reduction of AHRS less than 20% of the initial score. A partial response is defined as a reduction in a range of between 20% and 50% of the initial AHRS score. A complete response is defined as a reduction by at least 50% of the initial AHRS score.The combined outcome of protocol #8116 and the currently proposed protocol will help guide TMS targeting and the number of treatment sessions for a future larger randomized, double-blinded, shame-controlled clinical trial. ;

Study Design

Related Conditions & MeSH terms

Hallucinations
Schizophrenia
Schizophrenia and Related Disorders

Clinical Trial Details

NCT number	NCT05526833
Study type	Interventional
Source	Columbia University
Contact
Status	Terminated
Phase	N/A
Start date	September 12, 2022
Completion date	January 26, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05083377` - Clozapine Use Pattern in the Province of Seville
Recruiting	`NCT06313918` - Exercise Therapy in Mental Disorders-study	N/A
Recruiting	`NCT06134661` - Accelerated rTMS for Psychomotor Slowing	N/A
Completed	`NCT01433094` - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia	N/A
Recruiting	`NCT05982158` - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices	N/A
Active, not recruiting	`NCT06175559` - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia	N/A
Active, not recruiting	`NCT05673941` - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia	N/A
Recruiting	`NCT02916810` - TMS for Symptom Reduction in Schizophrenia	N/A
Recruiting	`NCT05958875` - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.	Phase 4
Recruiting	`NCT03525054` - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting	`NCT05389345` - tDCS and Executive Function Training for Schizophrenia	N/A
Completed	`NCT05601050` - Linguistic Predictors of Outcomes in Psychosis
Completed	`NCT03075202` - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed	`NCT03921450` - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)	N/A
Completed	`NCT06231407` - Increasing Medication Check Participation Through Applying CT-r	N/A
Recruiting	`NCT04478838` - "Extended" (Alternate Day) Antipsychotic Dosing	Phase 4
Completed	`NCT04366401` - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders	N/A
Completed	`NCT04612777` - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses	N/A
Not yet recruiting	`NCT06191965` - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction	Phase 2/Phase 3
Recruiting	`NCT04321759` - Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms